Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908537 | 0.90 | RXFP1 (0.56) | RXFP1P2RY12P2RX1P2RX3P2RX4 | |
| SCHEMBL23578588 | 0.90 | RXFP1 (0.56) | RXFP1P2RY12P2RX1P2RX3P2RX4 | |
| SCHEMBL1795447 | 0.90 | RXFP1 (0.58) | RXFP1P2RY12P2RX1P2RX3P2RX4 | |
| SCHEMBL15456117 | 0.85 | P2RY12 (0.51) | RXFP1P2RY12P2RX1P2RX3P2RX4 | |
| SCHEMBL14388686 | 0.85 | P2RY12 (0.51) | RXFP1P2RY12P2RX1P2RX3P2RX4 | |
| SCHEMBL14372074 | 0.85 | P2RY12 (0.52) | RXFP1P2RY12P2RX1P2RX3P2RX4 | |
| SCHEMBL11759931 | 0.85 | RXFP1 (0.63) | RXFP1P2RX1P2RX3P2RX4PI4KA | |
| SCHEMBL22601403 | 0.84 | PI4KA (0.62) | RXFP1P2RY12PI4KAPI4K2BPI4K2A | |
| SCHEMBL21504639 | 0.84 | PI4KA (0.52) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22402681 | 0.84 | PI4KA (0.62) | RXFP1P2RY12PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-18 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | SHANGHAI XINQI WU FILM AND TELEVISION INVESTMENT CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | LUMINEX INTERNATIONAL (CN) | 2020-09-10 | — | — | US | disclosed |
| CN-111565726-A | Compositions and methods for modulating immune responses by activating alpha protein kinase 1 | 上海药苑生物科技有限公司 | 2020-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | RXFP1 1354/4885P2RY12 1490/4885P2RX1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.